Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
November 2025
in “
Mendeley Data
”
TLDR Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
The study investigates the relationship between androgenetic alopecia (AGA) and prostate cancer risk, focusing on the use of 5-alpha reductase inhibitors (5-ARIs) in patients with AGA. Utilizing data from the TriNetX network, the research analyzed a real-world cohort to determine the impact of 5-ARIs on prostate cancer incidence. The findings suggest that patients with AGA who use 5-ARIs have a reduced risk of developing prostate cancer. This study highlights the potential protective effect of 5-ARIs against prostate cancer in individuals with AGA, providing valuable insights for clinical practice.
